Ishizaka T - Search Results

1

Visualization of cross-resistance between antimicrobial agents by asymmetric multidimensional scaling.

Hatsuda Y, Maki S, Ishizaka T, Omotani S, Koizumi N, Yasui Y, Saito T, Myotoku M, Okada A, Imaizumi T. Hatsuda Y, et al. Among authors: ishizaka t. J Clin Pharm Ther. 2022 Mar;47(3):345-359. doi: 10.1111/jcpt.13564. Epub 2021 Nov 24. J Clin Pharm Ther. 2022. PMID: 34818683 Free PMC article.

2

[Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients].

Fujii C, Kimura Y, Makari Y, Mikami J, Fujita J, Kamigaki S, Hayashi H, Yanagishita Y, Yasui Y, Ishizaka T. Fujii C, et al. Among authors: ishizaka t. Gan To Kagaku Ryoho. 2016 Nov;43(12):1960-1962. Gan To Kagaku Ryoho. 2016. PMID: 28133189 Japanese.

3

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir.

Omotani S, Ishizaka T, Inoue M, Nishida K, Yasui Y, Hatsuda Y, Mukai J, Myotoku M. Omotani S, et al. Among authors: ishizaka t. J Pharm Health Care Sci. 2020 Apr 2;6:6. doi: 10.1186/s40780-020-00162-y. eCollection 2020. J Pharm Health Care Sci. 2020. PMID: 32266075 Free PMC article.

4

Influence of analysis conditions for antimicrobial susceptibility test data on susceptibility rates.

Hatsuda Y, Ishizaka T, Koizumi N, Yasui Y, Saito T, Maki S, Omotani S, Mukai J, Tachi T, Teramachi H, Myotoku M. Hatsuda Y, et al. Among authors: ishizaka t. PLoS One. 2020 Jun 23;15(6):e0235059. doi: 10.1371/journal.pone.0235059. eCollection 2020. PLoS One. 2020. PMID: 32574199 Free PMC article.

5

Analysis of the predictive factors for a critical illness of COVID-19 during treatment － relationship between serum zinc level and critical illness of COVID-19.

Yasui Y, Yasui H, Suzuki K, Saitou T, Yamamoto Y, Ishizaka T, Nishida K, Yoshihara S, Gohma I, Ogawa Y. Yasui Y, et al. Among authors: ishizaka t. Int J Infect Dis. 2020 Nov;100:230-236. doi: 10.1016/j.ijid.2020.09.008. Epub 2020 Sep 7. Int J Infect Dis. 2020. PMID: 32911042 Free PMC article.

6

Monitoring antimicrobial cross-resistance with cross-resistance rate correlation diagrams: Changes in antibiotic susceptibility of Pseudomonas aeruginosa due to hospital relocation.

Hatsuda Y, Ishizaka T, Koizumi N, Yasui Y, Saito T, Omotani S, Maki S, Teramachi H, Myotoku M. Hatsuda Y, et al. Among authors: ishizaka t. J Clin Pharm Ther. 2021 Apr;46(2):395-407. doi: 10.1111/jcpt.13296. Epub 2020 Oct 28. J Clin Pharm Ther. 2021. PMID: 33113166

7

[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].

Tsurushima K, Yanagishita Y, Ogawa N, Fujii C, Yasui Y, Takeda T, Tsubaki M, Nishida S, Ishizaka T, Yamamura J, Kamigaki S. Tsurushima K, et al. Among authors: ishizaka t. Gan To Kagaku Ryoho. 2022 Jun;49(6):701-704. Gan To Kagaku Ryoho. 2022. PMID: 35799400 Japanese.

8

Bitterness evaluation of medicines for pediatric use by a taste sensor.

Ishizaka T, Miyanaga Y, Mukai J, Asaka K, Nakai Y, Tsuji E, Uchida T. Ishizaka T, et al. Chem Pharm Bull (Tokyo). 2004 Aug;52(8):943-8. doi: 10.1248/cpb.52.943. Chem Pharm Bull (Tokyo). 2004. PMID: 15304986 Free article.

9

Quantitative taste evaluation of total enteral nutrients.

Mukai J, Miyanaga Y, Ishizaka T, Asaka K, Nakai Y, Tsuji E, Uchida T. Mukai J, et al. Among authors: ishizaka t. Chem Pharm Bull (Tokyo). 2004 Dec;52(12):1416-21. doi: 10.1248/cpb.52.1416. Chem Pharm Bull (Tokyo). 2004. PMID: 15577236 Free article. Clinical Trial.

10

The suppression of enhanced bitterness intensity of macrolide dry syrup mixed with an acidic powder.

Ishizaka T, Okada S, Takemoto E, Tokuyama E, Tsuji E, Mukai J, Uchida T. Ishizaka T, et al. Chem Pharm Bull (Tokyo). 2007 Oct;55(10):1452-7. doi: 10.1248/cpb.55.1452. Chem Pharm Bull (Tokyo). 2007. PMID: 17917288 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

345 results

Search Page